Oncology
Refine Search
Pharmaceutical
Bristol Myers Squibb has posted better-than-expected second-quarter 2025 results, driven by strong sales of its blood thinner Eliquis (apixaban) and cancer treatments Opdivo (nivolumab) and Revlimid (lenalidomide). 31 July 2025
Pharmaceutical
Shares in French pharma major Sanofi were 6% lower late Thursday after the presentation of the company’s second quarter financial results and latest guidance. 31 July 2025
Pharmaceutical
Shares of US pharma major AbbVie were up 6.1% at $200.96 in pre-market activity, as it announced second-quarter 2025 financial results. 31 July 2025
Pharmaceutical
Ipsen has reported second-quarter 2025 sales of 901 million euros ($980 million), up 8% from the same period a year ago. Core earnings per share rose 27% to 6.07 euros ($6.60) as strength in rare disease products offset flat performance in oncology. 31 July 2025
Pharmaceutical
Swedish biotech Oncopeptides has entered into a partnership with Spanish pharmaceutical broker SD Pharma to boost the availability of its cancer drug Pepaxti (melphalan flufenamide) in hospitals across Spain. 30 July 2025
Pharmaceutical
GSK posted a 6% rise in second-quarter sales to £8 billion ($10.7 billion), ahead of analyst forecasts. Pre-tax profits climbed 37% to £1.9 billion, while core earnings per share increased 15% to 46.5p, supported by strength in specialty medicines and vaccines. 30 July 2025
Biotechnology
The UK’s National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for the use of AstraZeneca’s Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) as a treatment option for adult patients with advanced or unresectable hepatocellular carcinoma (HCC). 30 July 2025
Biotechnology
Japanese drugmaker revealed that its in-house discovered tyrosine kinase inhibitor, Lenvima (lenvatinib mesylate), in combination with the anti-PD-1 antibody, pembrolizumab, and transarterial chemoembolization (TACE) has been approved by the National Medical Products Administration (NMPA) of China for unresectable, non-metastatic hepatocellular carcinoma. 30 July 2025
Pharmaceutical
Japanese drugmaker Takeda has announced earnings results for the first quarter of Japan’s fiscal year 2025, ending June 30. 30 July 2025
Pharmaceutical
Artbio, a US biotech specializing in radiopharmaceuticals, has raised $132 million in a series B financing to move its lead prostate cancer candidate AB001 through Phase II trials and build out a decentralized manufacturing network. 30 July 2025
Pharmaceutical
Eli Lilly today announced positive top-line results from the Phase III BRUIN CLL-314 clinical trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, versus Imbruvica (ibrutinib), a covalent BTK inhibitor, in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). 29 July 2025
Pharmaceutical
US pharma giant Merck & Co was trading 4% lower in pre-market Tuesday after the group presented its second quarter 2025 financial results and guidance for the rest of the year. 29 July 2025
Pharmaceutical
Family-owned Boehringer Ingelheim, now Germany’s largest drugmaker by revenue, has reported positive growth in the first half of 2025, with group net sales growing by 6.3% to 14.0 billion euros ($14.7 billion). 29 July 2025
Pharmaceutical
AstraZeneca posted a robust second-quarter 2025 performance, lifted by record growth in its US business and solid momentum across its key therapy areas.
The UK pharma major reported revenue of $14.5 billion for the three months to June 30, up 12% from a year earlier and ahead of analysts’ forecasts. Pre-tax profit climbed 30% to $3.1 billion, while earnings per share rose 27% to $1.58. 29 July 2025
Pharmaceutical
US clinical-stage oncology focused biotech Celcuity saw its shares skyrocket 180% to $38.59 in early trading as it announced positive trial data for its lead candidate gedatolisib. 28 July 2025
Biotechnology
UK pharma major AstraZeneca this morning revealed that its supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) has been accepted and granted Priority Review in the USA for the treatment of patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers. 28 July 2025
Biotechnology
TCG Labs Soleil has secured another $400 million to expand its global R&D footprint and help build out its growing portfolio of single-asset biotechnology companies. The San Francisco-based venture firm said the new fund matches the size of its inaugural raise last year. 25 July 2025
Biotechnology
French drugmaker Ipsen announced that the European Commission (EC) has approved Cabometyx (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. 25 July 2025
Biotechnology
In an import contrast to events in the USA, UK pharma major GSK late Thursday announced the approval of Blenrep (belantamab mafodotin) by the European Commission. 25 July 2025
Biotechnology
Following the positive opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on June 19, 2025, the European Commission has approved French pharma major Sanofi's (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the induction treatment of adult patients with newly diagnosed multiple myeloma (NDMM) who are eligible for autologous stem cell transplant. 25 July 2025
Biotechnology
Akari Therapeutics, a US biotech developing next-generation bi-functional antibody drug conjugates (ADCs) for the treatment of cancer, has announced the appointment of Abizer Gaslightwala as president and chief executive. 20 March 2025
Pharmaceutical
Today, Cambridge, USA-based clinical-stage oncology company Immuneering announced the appointment of Dr Igor Matushansky as chief medical officer (CMO). 20 March 2025
Biotechnology
Elevation Oncology has decided to discontinue development of EO-3021, a Claudin 18.2 antibody-drug conjugate (ADC) which was being developed for the treatment of advanced, unresectable or metastatic gastric and gastroesophageal junction (GEJ) cancers. 20 March 2025
Biotechnology
Chugai Pharmaceutical has launched Lunsumio (mosunetuzumab) in Japan for patients with relapsed or refractory follicular lymphoma who have undergone at least two prior standard therapies. 20 March 2025
Biotechnology
Chimeric antigen receptor T-cell (CAR-T) therapeutics have emerged as a dominating cancer treatment within cell and gene therapies (CGT). 20 March 2025
Biotechnology
Japanese drugmaker Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been launched in the company’s home country for the treatment of adults with hormone receptor (HR) positive, HER2 negative, unresectable or recurrent breast cancer after prior chemotherapy. 20 March 2025
Pharmaceutical
Whitehawk Therapeutics , formerly Aadi Bioscience, has officially rebranded to reflect its transformation into a pre-clinical-stage biotech focused on antibody-drug conjugates (ADCs). 19 March 2025
Pharmaceutical
French independent pharma firm Servier and USA-based Black Diamond Therapeutics, a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced a strategic worldwide licensing agreement for BDTX-4933, a potential best-in-class targeted therapy for solid tumors 19 March 2025
Biotechnology
Chinese pair Hutchmed and Innovent Biologics have announced that the FRUSICA-2 Phase II/III trial of fruquintinib and sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma (RCC) in China has met its primary endpoint. 19 March 2025
Biotechnology
Shares of French late-stage clinical biotech firm Nanobiotix leapt 17.6% to 3.47 euros after it announced the execution of another disciplined step in its financial strategy through the amendment of its global licensing agreement with Johnson & Johnson subsidiary Janssen entered into in 2023 to develop its radioenhancer NBTXR3. 18 March 2025
Biotechnology
European life sciences venture capital firm Sofinnova Partners and French cancer research hospital Gustave Roussy have announced the creation of their first biotech company. 18 March 2025
Biotechnology
Californian cell therapy company Orca Bio has announced positive results from the pivotal Phase III Precision-T study of Orca-T, its lead investigational allogeneic T-cell immunotherapy, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), high-risk myelodysplastic syndrome (MDS) and mixed-phenotype acute leukemia (MPAL). 18 March 2025
Generics
The Russian drugmaker Axelpharm will continue sales of its drug axitinib, which is used in kidney cancer therapy and is a generic of version of US pharma giant Pfizer’s Inlyta, reports The Pharma Letter’s local correspondent.
drug of the US Pfizer. 18 March 2025
Biotechnology
Japanese drugmaker Otsuka Holdings’ subsidiary Taiho Pharmaceuticals is to buy Araris Biotech, a Swiss oncology firm developing antibody drug conjugates (ADCs). 17 March 2025
Biotechnology
Switzerland-headquartered iOnctura today announced the appointments of Elizabeth Holt as chief business officer (CBO) and Dr Mark Velleca as chairman of the board of directors. 17 March 2025
Biotechnology
AstraZeneca today revealed it has entered into a definitive agreement to acquire EsoBiotec, a Belgium-based biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. 17 March 2025
Pharmaceutical
Anglo-Swedish pharma major AstraZeneca and Korean biotech Alteogen have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase using Hybrozyme platform technology. 17 March 2025
Biotechnology
The European Commission (EC) has granted approval to Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy from Bristol Myers Squibb, for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. 17 March 2025
Biotechnology
The American Academy of Dermatology (AAD) meeting last week continued to provide positive news, including from US biotech Amgen and Japan’s Kyowa Kirin, with Phase III results for their rocatinlimab as a potential treatment for severe atopic dermatitis. In other news, Denmark’s Novo Nordisk released new data for its obesity hopeful CagriSema, which again failed to impress. Last week also saw US biotech 2seventy bio accept a takeover bid from Bristol Myers Squibb along with their partnered CAR-T cell therapy Abecma. Additionally, USA-based Sareum Holdings has in-licensed a cancer candidate, SRA737, from an unnamed company. 16 March 2025
Pharmaceutical
Guaranteed success in drug development does not exist, such are the inherent risks, potential pitfalls and costs involved. But UK-based Ellipses Pharma has developed a model that - if its founder’s convictions prove accurate - will maximize the probability of success and lead to a host of new oncology drugs being brought to market by big pharma. 14 March 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze